Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31234430 | 0.81 | NAMPT (0.44) | NAMPTPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL31234220 | 0.79 | ACACB (0.44) | NAMPTPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL31234399 | 0.77 | PIK3CD (0.42) | NAMPTPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL31234281 | 0.75 | PIK3CD (0.46) | NAMPTPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL31234733 | 0.74 | PIK3CD (0.42) | NAMPTPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL26907230 | 0.70 | BTK (0.42) | NAMPTPIK3CDPIK3CA | |
| SCHEMBL27115842 | 0.70 | BTK (0.42) | NAMPTPIK3CDPIK3CA | |
| SCHEMBL26988825 | 0.70 | BTK (0.42) | NAMPTPIK3CDPIK3CA | |
| SCHEMBL31234493 | 0.70 | NAMPT (0.50) | NAMPTPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30722716 | 0.68 | PIK3CD (0.53) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | INCYTE CORP (US) | 2024-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | KRAS, NRAS, HRAS | NAMPT 2617/4885PIK3CD 121/4885PIK3CA 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.